These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 19035668

  • 21. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors.
    Orlova A, Tolmachev V, Pehrson R, Lindborg M, Tran T, Sandström M, Nilsson FY, Wennborg A, Abrahmsén L, Feldwisch J.
    Cancer Res; 2007 Mar 01; 67(5):2178-86. PubMed ID: 17332348
    [Abstract] [Full Text] [Related]

  • 22. Synthesis and chemoselective intramolecular crosslinking of a HER2-binding affibody.
    Ekblad T, Tolmachev V, Orlova A, Lendel C, Abrahmsén L, Karlström AE.
    Biopolymers; 2009 Mar 01; 92(2):116-23. PubMed ID: 19140162
    [Abstract] [Full Text] [Related]

  • 23. Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA.
    Altai M, Perols A, Karlström AE, Sandström M, Boschetti F, Orlova A, Tolmachev V.
    Nucl Med Biol; 2012 May 01; 39(4):518-29. PubMed ID: 22172396
    [Abstract] [Full Text] [Related]

  • 24. In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules.
    Tran T, Engfeldt T, Orlova A, Widström C, Bruskin A, Tolmachev V, Karlström AE.
    Bioconjug Chem; 2007 May 01; 18(2):549-58. PubMed ID: 17330952
    [Abstract] [Full Text] [Related]

  • 25. Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)Re.
    Altai M, Honarvar H, Wållberg H, Strand J, Varasteh Z, Rosestedt M, Orlova A, Dunås F, Sandström M, Löfblom J, Tolmachev V, Ståhl S.
    Eur J Med Chem; 2014 Nov 24; 87():519-28. PubMed ID: 25282673
    [Abstract] [Full Text] [Related]

  • 26. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
    Orlova A, Nilsson FY, Wikman M, Widström C, Ståhl S, Carlsson J, Tolmachev V.
    J Nucl Med; 2006 Mar 24; 47(3):512-9. PubMed ID: 16513621
    [Abstract] [Full Text] [Related]

  • 27. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules.
    Ahlgren S, Orlova A, Rosik D, Sandström M, Sjöberg A, Baastrup B, Widmark O, Fant G, Feldwisch J, Tolmachev V.
    Bioconjug Chem; 2008 Jan 24; 19(1):235-43. PubMed ID: 18163536
    [Abstract] [Full Text] [Related]

  • 28. Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies.
    Cyr JE, Pearson DA, Wilson DM, Nelson CA, Guaraldi M, Azure MT, Lister-James J, Dinkelborg LM, Dean RT.
    J Med Chem; 2007 Mar 22; 50(6):1354-64. PubMed ID: 17315859
    [Abstract] [Full Text] [Related]

  • 29. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT.
    Gainkam LO, Huang L, Caveliers V, Keyaerts M, Hernot S, Vaneycken I, Vanhove C, Revets H, De Baetselier P, Lahoutte T.
    J Nucl Med; 2008 May 22; 49(5):788-95. PubMed ID: 18413403
    [Abstract] [Full Text] [Related]

  • 30. HAHAHA, HEHEHE, HIHIHI, or HKHKHK: influence of position and composition of histidine containing tags on biodistribution of [(99m)Tc(CO)3](+)-labeled affibody molecules.
    Hofström C, Altai M, Honarvar H, Strand J, Malmberg J, Hosseinimehr SJ, Orlova A, Gräslund T, Tolmachev V.
    J Med Chem; 2013 Jun 27; 56(12):4966-74. PubMed ID: 23692562
    [Abstract] [Full Text] [Related]

  • 31. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Orlova A, Jonsson A, Rosik D, Lundqvist H, Lindborg M, Abrahmsen L, Ekblad C, Frejd FY, Tolmachev V.
    J Nucl Med; 2013 Jun 27; 54(6):961-8. PubMed ID: 23528382
    [Abstract] [Full Text] [Related]

  • 32. In vivo and in vitro characterization of CCK8 bearing a histidine-based chelator labeled with 99mTc-tricarbonyl.
    D'Andrea LD, Testa I, Panico M, Di Stasi R, Caracò C, Tarallo L, Arra C, Barbieri A, Romanelli A, Aloj L.
    Biopolymers; 2008 Jun 27; 90(5):707-12. PubMed ID: 18615495
    [Abstract] [Full Text] [Related]

  • 33. Influence of the molecular charge on the biodistribution of bombesin analogues labeled with the [99mTc(CO)3]-core.
    García Garayoa E, Schweinsberg C, Maes V, Brans L, Bläuenstein P, Tourwe DA, Schibli R, Schubiger PA.
    Bioconjug Chem; 2008 Dec 27; 19(12):2409-16. PubMed ID: 18998719
    [Abstract] [Full Text] [Related]

  • 34. Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule.
    Vernet E, Konrad A, Lundberg E, Nygren PA, Gräslund T.
    J Immunol Methods; 2008 Sep 30; 338(1-2):1-6. PubMed ID: 18671978
    [Abstract] [Full Text] [Related]

  • 35. Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules.
    Tolmachev V, Xu H, Wållberg H, Ahlgren S, Hjertman M, Sjöberg A, Sandström M, Abrahmsén L, Brechbiel MW, Orlova A.
    Bioconjug Chem; 2008 Aug 30; 19(8):1579-87. PubMed ID: 18620447
    [Abstract] [Full Text] [Related]

  • 36. Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate.
    Tolmachev V, Feldwisch J, Lindborg M, Baastrup B, Sandström M, Orlova A.
    Nucl Med Biol; 2011 Jul 30; 38(5):697-706. PubMed ID: 21718945
    [Abstract] [Full Text] [Related]

  • 37. Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.
    Engfeldt T, Orlova A, Tran T, Bruskin A, Widström C, Karlström AE, Tolmachev V.
    Eur J Nucl Med Mol Imaging; 2007 May 30; 34(5):722-733. PubMed ID: 17146656
    [Abstract] [Full Text] [Related]

  • 38. Biodistribution of 211At labeled HER-2 binding affibody molecules in mice.
    Steffen AC, Almqvist Y, Chyan MK, Lundqvist H, Tolmachev V, Wilbur DS, Carlsson J.
    Oncol Rep; 2007 May 30; 17(5):1141-7. PubMed ID: 17390057
    [Abstract] [Full Text] [Related]

  • 39. Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma.
    Fortin MA, Orlova A, Malmström PU, Tolmachev V.
    Int J Mol Med; 2007 Feb 30; 19(2):285-91. PubMed ID: 17203203
    [Abstract] [Full Text] [Related]

  • 40. Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules site-specifically labeled with (99m)Tc, (111)In, and (125)I.
    Hofstrom C, Orlova A, Altai M, Wangsell F, Graslund T, Tolmachev V.
    J Med Chem; 2011 Jun 09; 54(11):3817-26. PubMed ID: 21524142
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.